# International Consensus Classification of myeloid neoplasms and acute leukaemias (2022)

Source: https://onco.cc/key-papers/paper-icc-2022-arber-blood-2022/  
OnCo record `paper-icc-2022-arber-blood-2022` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A parallel classification to the WHO 2022 edition from an international expert group, which among other changes creates an MDS/AML category for 10 to 19 percent blasts and gives TP53-mutated disease its own entities.

## Summary

Classification of myeloid neoplasms and acute leukaemias integrating morphology, clinical features and genomics, produced by the International Consensus Classification group, with new categories for MDS/AML, TP53-mutated myeloid neoplasms and genetically defined AML subtypes at lower blast thresholds.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Blood
- Year: 2022
- DOI: 10.1182/blood.2022015850
- Authors: Arber DA, Orazi A, Hasserjian RP, et al.
- What it means: Trial eligibility and risk stratification in AML and MDS often refer to this classification alongside the WHO edition; the two overlap heavily but not completely.
- Caveats: Coexists with the WHO fifth edition, so the same marrow may carry two names.

## Sources

- Blood 2022: https://doi.org/10.1182/blood.2022015850
- PubMed: https://pubmed.ncbi.nlm.nih.gov/35767897/

## Connected records

- cancers: [Higher-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-higher-risk/)
- journals: [Blood](https://onco.cc/journals/blood/)

---
JSON: https://onco.cc/api/v1/entities/paper-icc-2022-arber-blood-2022.json